Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Japan iPS Patent Could Go To Germany’s Bayer, Office Says

This article was originally published in PharmAsia News

Executive Summary

The future of Japan's effort to promote research into induced pluripotent stem cells could hinge on a decision by the country's Patent Office. It found that Germany's Bayer had applied for several similar patents, including one for Kyoto University's method, three months before the Japanese researchers. If Bayer eventually is awarded the patent, observers expect Japanese patent rights to become so complicated the government's iPS research promotion policy could itself be affected. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts